MHRA Publishes In Vitro Diagnostic Roadmap to Drive Innovation and Patient Care
The Medicines and Healthcare products Regulatory Agency (MHRA) has released its In Vitro Diagnostic (IVD) Roadmap, outlining key deliverables and timelines for 2026–2027. This roadmap supports the development and adoption of innovative diagnostic technologies that improve patient outcomes through faster, more accurate testing.
The plan focuses on three core themes:
- Regulatory support for new technologies – including guidance for companion diagnostics.
- Regulatory science and research – promoting standards and reference materials for emerging diagnostics.
- Pandemic preparedness and resilience – strengthening frameworks and international collaboration for future health emergencies.
The roadmap aligns with commitments in the 10-Year Health Plan and Life Sciences Sector Plan, aiming to expand diagnostics into community settings and accelerate access to cutting-edge solutions like NGS-based cancer diagnostics and genetic testing.
Read the full roadmap here: In Vitro Diagnostic roadmap – GOV.UK
